SHANGHAI – Huya Bioscience International, with offices in San Diego, Tokyo and eight more across China, has set up its first China joint venture (JV) with the Tianjin Institute of Pharmaceutical Research (TIPR). The new entity is seeking to develop innovative therapeutics as well medical devices for China and global markets.

SHANGHAI – BGI, a powerhouse gene sequencing organization based in China, and the Vancouver Prostate Centre agreed to formalize their relationship by establishing a joint translational cancer research laboratory in Vancouver, British Columbia. They will use genome research to develop new biomarkers and cancer therapies, initially focusing on drug-resistant forms of bladder, kidney and prostate cancers.

SHANGHAI – After a 15-month corruption investigation, the verdict for Glaxosmithkline plc in China has been guilty as charged, surprising few industry insiders. It is routine for the government to come out on top in such high-profile cases, while most readily admit there are no saints in China's downstream pharmaceutical business.

SHANGHAI – Huya Bioscience International, with offices in San Diego, Tokyo and eight more across China, has set up its first China joint venture (JV) with the Tianjin Institute of Pharmaceutical Research (TIPR). The new entity is seeking to develop innovative therapeutics as well medical devices for China and global markets.

SHANGHAI – BGI, a powerhouse gene sequencing organization based in China, and the Vancouver Prostate Centre agreed to formalize their relationship by establishing a joint translational cancer research laboratory in Vancouver, British Columbia.

SHANGHAI – Beike Biotechnology Co. Ltd., a pioneer in China's stem cell industry, has entered a partnership with Altor Bioscience Corp. in a two-part licensing and equity deal. On the front end, Altor will see its coffers increase by $9 million, in a deal worth potentially $200 million in milestones and sales royalties. The agreement gives Beike the rights to develop and commercialize ALT-803, an interleukin-15 based superagonist complex in China, for all human disease indications.

SHANGHAI – Beike Biotechnology Co. Ltd., a pioneer in China's stem cell industry, has entered a partnership with Altor Bioscience Corp. in a two-part licensing and equity deal. On the front end, Altor will see its coffers increase by $9 million, in a deal worth potentially $200 million in milestones and sales royalties.

SHANGHAI – Eddingpharm Co. Ltd. began in 2001 by working with global companies in the spirit of partnership, by capitalizing on its knowledge of the China market for both its own and its partner's advantage. A second deal with nanobody developer Ablynx NV in less than a year shows it's continuing in this vein, making forays into the hairier terrain of biologics.

SHANGHAI – GC-Rise Pharmaceutical Co. Ltd. has received $15 million in series B financing from Orbimed Asia to pursue a strategy of in-licensing and commercializing products from the West to meet the growing health needs of women and children in China.